{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:45:35Z","timestamp":1788864335798,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ascendis Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40271-019-00388-5","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T05:09:16Z","timestamp":1569388156000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom)"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-5838","authenticated-orcid":false,"given":"Meryl","family":"Brod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Tesler","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Karpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"388_CR1","doi-asserted-by":"publisher","first-page":"17080","DOI":"10.1038\/nrdp.2017.80","volume":"3","author":"M Mannstadt","year":"2017","unstructured":"Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017;3:17080. https:\/\/doi.org\/10.1038\/nrdp.2017.80 .","journal-title":"Nat Rev Dis Primers."},{"issue":"10","key":"388_CR2","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317\u201337. https:\/\/doi.org\/10.1002\/jbmr.483 .","journal-title":"J Bone Miner Res."},{"issue":"1","key":"388_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/17446651.2015.971755","volume":"10","author":"NE Cusano","year":"2015","unstructured":"Cusano NE, Rubin MR, Bilezikian JP. PTH(1\u201384) replacement therapy for the treatment of hypoparathyroidism. Expert Rev Endocrinol Metab. 2015;10(1):5\u201313. https:\/\/doi.org\/10.1586\/17446651.2015.971755 .","journal-title":"Expert Rev Endocrinol Metab."},{"issue":"8","key":"388_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/0026-0495(76)90124-4","volume":"25","author":"AM Parfitt","year":"1976","unstructured":"Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976;25(8):909\u201355.","journal-title":"Metabolism."},{"issue":"1","key":"388_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/bulm.1999.0146","volume":"62","author":"MH Kroll","year":"2000","unstructured":"Kroll MH. Parathyroid hormone temporal effects on bone formation and resorption. Bull Math Biol. 2000;62(1):163\u201388. https:\/\/doi.org\/10.1006\/bulm.1999.0146 .","journal-title":"Bull Math Biol."},{"issue":"10","key":"388_CR6","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16(10):1846\u201353. https:\/\/doi.org\/10.1359\/jbmr.2001.16.10.1846 .","journal-title":"J Bone Miner Res."},{"key":"388_CR7","unstructured":"National Organization for Rare Disorders. Hypoparathyroidism. Resource document. 2017. https:\/\/rarediseases.org\/rare-diseases\/hypoparathyroidism\/ . Accessed 10 Oct 2018."},{"issue":"S1","key":"388_CR8","first-page":"S182","volume":"26","author":"BL Clarke","year":"2011","unstructured":"Clarke BL, Leibson C, Emerson J, Ransom JE, Lagast H. Co-morbid-medical conditions associated with prevalent hypoparathyroidism: a population-based study [abstract SA0170]. J Bone Miner Res. 2011;26(S1):S182.","journal-title":"J Bone Miner Res."},{"issue":"6","key":"388_CR9","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT, Juppner H, Lakatos P, Levine MA, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284\u201399. https:\/\/doi.org\/10.1210\/jc.2015-3908 .","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"388_CR10","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, L\u00f8v\u00e5s K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045\u201353.","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"388_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10875-015-0176-y","volume":"35","author":"K Kisand","year":"2015","unstructured":"Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol. 2015;35(5):463\u201378. https:\/\/doi.org\/10.1007\/s10875-015-0176-y .","journal-title":"J Clin Immunol."},{"issue":"3","key":"388_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/bf03350414","volume":"2","author":"KS Nair","year":"1979","unstructured":"Nair KS, Holdaway IM, Evans MC, Cameron AD. Influence of magnesium on the secretion and action of parathyroid hormone. J Endocrinol Investig. 1979;2(3):267\u201370. https:\/\/doi.org\/10.1007\/bf03350414 .","journal-title":"J Endocrinol Investig."},{"issue":"2","key":"388_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0022-3476(05)80486-X","volume":"118","author":"G Saggese","year":"1991","unstructured":"Saggese G, Federico G, Bertelloni S, Baroncelli GI, Calisti L. Hypomagnesemia and the parathyroid hormone-vitamin D endocrine system in children with insulin-dependent diabetes mellitus: effects of magnesium administration. J Pediatr. 1991;118(2):220\u20135.","journal-title":"J Pediatr."},{"issue":"4","key":"388_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D. Clinical practice: hypoparathyroidism. N Engl J Med. 2008;359(4):391\u2013403. https:\/\/doi.org\/10.1056\/NEJMcp0803050 .","journal-title":"N Engl J Med."},{"key":"388_CR15","unstructured":"Shire-NPS Pharmaceuticals. Natpara\u00ae prescribing guide. 2018. https:\/\/www.shirecontent.com\/PI\/PDFs\/Natpara_USA_ENG.pdf . Accessed 16 Oct 2018."},{"issue":"11","key":"388_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/bf03346763","volume":"36","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, Irani D, Sliney J Jr, Bilezikian JP. Use of parathyroid hormone in hypoparathyroidism. J Endocrinol Investig. 2013;36(11):1121\u20137. https:\/\/doi.org\/10.1007\/bf03346763 .","journal-title":"J Endocrinol Investig."},{"issue":"6","key":"388_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25(6):1717\u201326. https:\/\/doi.org\/10.1007\/s00198-014-2677-6 .","journal-title":"Osteoporos Int."},{"issue":"7","key":"388_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/jbmr.2812","volume":"31","author":"T Sikjaer","year":"2016","unstructured":"Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, et al. Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res. 2016;31(7):1440\u20138. https:\/\/doi.org\/10.1002\/jbmr.2812 .","journal-title":"J Bone Miner Res."},{"issue":"2","key":"388_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215\u201322.","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"388_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/ep13328.or","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014;20(7):671\u20139. https:\/\/doi.org\/10.4158\/ep13328.or .","journal-title":"Endocr Pract."},{"issue":"1","key":"388_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","volume":"58","author":"M Buttner","year":"2017","unstructured":"Buttner M, Musholt TJ, Singer S. Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine. 2017;58(1):14\u201320. https:\/\/doi.org\/10.1007\/s12020-017-1377-3 .","journal-title":"Endocrine."},{"issue":"2","key":"388_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-017-1479-y","volume":"59","author":"L Rejnmark","year":"2018","unstructured":"Rejnmark L. Quality of life in hypoparathyroidism. Endocrine. 2018;59(2):237\u20138. https:\/\/doi.org\/10.1007\/s12020-017-1479-y .","journal-title":"Endocrine."},{"key":"388_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bone.2018.09.017","volume":"120","author":"T Vokes","year":"2019","unstructured":"Vokes T. Quality of life in hypoparathyroidism. Bone. 2019;120:542\u20137. https:\/\/doi.org\/10.1016\/j.bone.2018.09.017 .","journal-title":"Bone."},{"key":"388_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bone.2018.09.018","volume":"120","author":"KK Winer","year":"2019","unstructured":"Winer KK. Advances in the treatment of hypoparathyroidism with PTH 1\u201334. Bone. 2019;120:535\u201341. https:\/\/doi.org\/10.1016\/j.bone.2018.09.018 .","journal-title":"Bone."},{"key":"388_CR25","unstructured":"US Department of Health and Human Services. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download . Accessed 7 June 2019."},{"issue":"9","key":"388_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s11136-009-9540-9","volume":"18","author":"M Brod","year":"2009","unstructured":"Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18(9):1263\u201378. https:\/\/doi.org\/10.1007\/s11136-009-9540-9 .","journal-title":"Qual Life Res."},{"issue":"8","key":"388_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11136-010-9677-6","volume":"19","author":"KE Lasch","year":"2010","unstructured":"Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19(8):1087\u201396. https:\/\/doi.org\/10.1007\/s11136-010-9677-6 .","journal-title":"Qual Life Res."},{"issue":"8","key":"388_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity: establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation. ISPOR PRO good research practices task force report. Part 2. Assessing respondent understanding. Value Health. 2011;14(8):978\u201388. https:\/\/doi.org\/10.1016\/j.jval.2011.06.013 .","journal-title":"Value Health"},{"issue":"8","key":"388_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity: establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation. ISPOR PRO good research practices task force report. Part 1. Eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014 .","journal-title":"Value Health."},{"issue":"1","key":"388_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1468794104041110","volume":"4","author":"JE Sturges","year":"2004","unstructured":"Sturges JE, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107\u201318.","journal-title":"Qual Res."},{"issue":"1","key":"388_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1468794109348686","volume":"10","author":"A Holt","year":"2010","unstructured":"Holt A. Using the telephone for narrative interviewing: a research note. Qual Res. 2010;10(1):113\u201321.","journal-title":"Qual Res."},{"issue":"1","key":"388_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1473325015585613","volume":"15","author":"L Drabble","year":"2016","unstructured":"Drabble L, Trocki KF, Salcedo B, Walker PC, Korcha RA. Conducting qualitative interviews by telephone: lessons learned from a study of alcohol use among sexual minority and heterosexual women. Qual Soc Work. 2016;15(1):118\u201333.","journal-title":"Qual Soc Work."},{"key":"388_CR33","doi-asserted-by":"publisher","DOI":"10.4135\/9781452230153","volume-title":"Basics of qualitative research. 3rd ed. Techniques and procedures for developing grounded theory","author":"J Corbin","year":"2008","unstructured":"Corbin J, Strauss A. Basics of qualitative research. 3rd ed. Techniques and procedures for developing grounded theory. Thousand Oaks: Sage Publications, Inc.; 2008. https:\/\/doi.org\/10.4135\/9781452230153 ."},{"issue":"6","key":"388_CR34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1046\/j.1365-2648.2000.01430.x","volume":"31","author":"JR Cutcliffe","year":"2000","unstructured":"Cutcliffe JR. Methodological issues in grounded theory. J Adv Nurs. 2000;31(6):1476\u201384.","journal-title":"J Adv Nurs."},{"key":"388_CR35","doi-asserted-by":"crossref","DOI":"10.1002\/9781394260645","volume-title":"Internet, phone, mail, and mixed-mode surveys: the tailored design method","author":"DA Dillman","year":"2014","unstructured":"Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and mixed-mode surveys: the tailored design method. 4th ed. Hoboken: Wiley; 2014.","edition":"4"},{"issue":"8","key":"388_CR36","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, Lovas K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045\u201353. https:\/\/doi.org\/10.1210\/jc.2016-1477 .","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"388_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PROM.S179310","volume":"29","author":"T Coles","year":"2019","unstructured":"Coles T, Chen K, Nelson L, Harris N, Vera-Llonch M, Krasner A, et al. Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas. 2019;29(10):25\u201336.","journal-title":"Patient Relat Outcome Meas."},{"issue":"7","key":"388_CR38","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/jc.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, et al. Therapy of hypoparathyroidism with PTH(1\u201384): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101(7):2742\u201350. https:\/\/doi.org\/10.1210\/jc.2015-4135 .","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"388_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1530\/eje-12-0946","volume":"168","author":"S Aggarwal","year":"2013","unstructured":"Aggarwal S, Kailash S, Sagar R, Tripathi M, Sreenivas V, Sharma R, et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168(6):895\u2013903. https:\/\/doi.org\/10.1530\/eje-12-0946 .","journal-title":"Eur J Endocrinol."},{"issue":"Suppl 1","key":"388_CR40","first-page":"i","volume":"38","author":"K Chen","year":"2017","unstructured":"Chen K, Krasner A, Li N, Xiang C, Sourotzidis A, Xie J. Clinical and economic burden associated with chronic hypoparathyroidism: a retrospective chart review in the United States, Canada, United Kingdom, France, Germany, Italy, and Spain (abstract). Endocr Rev. 2017;38(Suppl 1):i.","journal-title":"Endocr Rev."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-019-00388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:56:24Z","timestamp":1721768184000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-019-00388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40271-019-00388-5","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"25 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Ascendis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Meryl Brod and Laura Tesler Waldman are consultants to the pharmaceutical industry, including Ascendis Pharma. Alden Smith is an employee of Ascendis Pharma and received stock options as an employee of Ascendis Pharma. David Karpf is an employee of Ascendis Pharma and received stock\/stock options as an employee of Ascendis Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Copernicus Group Institutional Review Board, tracking #420180290) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The data for the research presented in the publication may be available from the corresponding author, on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}